TON - Supplements
From 2004 to 2013, 22 new oral anticancer medications were introduced in the United States, which is almost the same number (27) of oral anticancer medications that were introduced in the previous 50 years combined. Of the US Food and Drug Administration (FDA)-approved myeloma novel therapies, 5 are orally administered. With the FDA approval of ixazomib (Ninlaro; a first-in-class oral proteasome inhibitor) in November 2015, an all-oral treatment combination for patients with myeloma is now a reality with the combination of ixazomib, lenalidomide (Revlimid), and dexamethasone (Decadron)

Read More
Last modified: March 3, 2016